CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday

CRISPR Therapeutics (NASDAQ:CRSP) is projected to issue its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 12:00 AM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $51.31 on Tuesday. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The business has a 50 day moving average price of $55.08 and a 200 day moving average price of $58.27. The company has a market capitalization of $4.89 billion, a P/E ratio of -9.18 and a beta of 1.72.

Insider Activity

In related news, CEO Samarth Kulkarni sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the sale, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Royal Bank of Canada boosted its holdings in CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after acquiring an additional 31,392 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at about $861,000. Woodline Partners LP grew its holdings in shares of CRISPR Therapeutics by 34.3% during the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after purchasing an additional 34,883 shares during the period. Prudential Financial Inc. purchased a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $237,000. Finally, Invesco Ltd. raised its holdings in CRISPR Therapeutics by 138.4% in the second quarter. Invesco Ltd. now owns 66,648 shares of the company’s stock valued at $3,242,000 after buying an additional 38,691 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wedbush reduced their price objective on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Citizens Jmp reduced their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Bank of America cut their price objective on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a research report on Monday, October 13th. Twelve equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $67.85.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.